Skip to main content
. 2021 Jul 2;22(13):7183. doi: 10.3390/ijms22137183

Figure 1.

Figure 1

Behavioral tests following 5-weeks treatment. (A) Spontaneous locomotor activity—mean ± S.E.M (standard error of the mean) of total number of horizontal movements. (B) Mean and 95% confidence interval estimates of the horizontal movements after treatment. (C) Spontaneous locomotor activity—mean ± S.E.M of total number of vertical movements. (D) Mean and 95% confidence interval estimates of the vertical movements after treatment. (E) Motor coordination— mean ± S.E.M of latency (s) of falls off the rotating drum. (F) Mean and 95% confidence interval estimates of the fall latencies after treatment. (G) Cold temperature sensitivity— mean ± S.E.M of total pain reaction score. (H) Mean and 95% confidence interval estimates of the pain reaction score after treatment. CTL—control (n = 10); CPZ—cuprizone 400 mg·kg−1 (n = 10); CPZ + VEN—cuprizone 400 mg·kg−1 and venlafaxine 60 mg·kg−1 (n = 8); CPZ + RSP—cuprizone 400 mg·kg−1 and risperidone 2 mg·kg−1 (n = 8); CPZ + FEB—cuprizone 400 mg·kg−1 and febuxostat 5 mg·kg−1 (n = 8). Baseline measurements for the corresponding tests before treatment were used as covariates for estimation in panels B, D, F and H. * p < 0.05 vs. CTL; # p < 0.05 vs. CPZ.